EnvirOx Launches Critical Care Disinfectant Containing Innovative Medical Services' Axenohl Technology.

Business Editors/Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--Sept. 16, 2003

New Industrial Disinfectant Delivers Better, Faster Disinfecting Power

Innovative Medical Services (NASDAQ:PURE) today announced that EnvirOx, L.L.C. of Danville, Illinois, has launched Critical Care(TM), a new commercial disinfectant-fungicide-virucide, featuring Axen-30(TM) as the active ingredient.

Michael L. Krall, president and CEO of Innovative Medical Services stated, "EnvirOx's leading-edge business is based upon addressing difficult cleaning challenges while reducing human and environmental toxicity in a meaningful way. The launch of Critical Care by EnvirOx reflects the prevailing trend of an entire industry - a transition from traditional poisonous chemicals to reduced toxicity, high efficacy janitorial and sanitation products. We believe that our Axenohl(TM) technology will be on the forefront of this evolution."

"Response so far to Critical Care has been remarkable," stated Patrick Stewart, president of EnvirOx, L.L.C.. "For the first time, professionals can disinfect a surface, have a very fast kill and know there is a residual kill for up to 24 hours. It's the Axen-30 silver ion technology that enables the product to kill most common bacteria in just 30 seconds and coat a non-porous surface with residual protection that lasts 24 hours. You get a safe, low toxicity product that delivers better, faster disinfecting power that lasts."

Innovative Medical Services and EnvirOx together have obtained U.S. Environmental Protection Agency registration for Critical Care, and EnvirOx has already attained approval to sell Critical Care in many US states.

Axen-30 Disinfectant Sets New Industry Standard

Axen-30 is an EPA approved 30 parts-per-million (ppm) use-dilution formula of Innovative Medical Services' new molecule, Axenohl. Efficacy claims for Axen-30 include a 30-second kill time on standard indicator bacteria; a 24-hour residual kill on standard indicator bacteria; a 2-minute kill time on the resistant strains of bacteria, MRSA and VRE; a 10-minute kill time on fungi; a 30-second kill time on HIV Type I; and a 10-minute kill time on certain other viruses. These claims distinguish the efficacy of Axen-30 from many leading commercial and consumer products currently on the market; furthermore, Axen-30 maintains lowest toxicity ratings. Innovative Medical Services plans to pursue EPA approvals for additional applications including disinfecting wipes, food contact surface sanitization and water treatment.

Wide Ranging Potential of Axenohl

The potential marketability of Innovative Medical Services' Axenohl technology reaches beyond EPA applications into human healthcare treatments. Innovative Medical Services recently announced that it has signed an agreement with Therapeutics, Inc., a drug development company based in La Jolla, California, for the development and commercialization of Food and Drug Administration (FDA) regulated Axenohl(R)-based products. Under the terms of the agreement, Therapeutics, Inc., will be responsible for funding and directing all development activities and regulatory filings.

About EnvirOx, L.L.C.

EnvirOx, L.L.C., is headquartered in Danville, Ill., and specializes in the manufacturing and marketing of hydrogen peroxide-based, low toxicity cleaning products. Its H(2)Orange(2) Multi-Purpose Concentrate 117 was the industry's first hydrogen peroxide-based cleaning product, and is EPA registered, Green Seal GS-37 certified and NSF rated A1, D2. The company's Grout-Safe Tile and Grout Cleaner is also Green Seal certified and NSF rated A1. Currently, the company offers nine different low toxicity cleaning products, as well as proprietary personal and wall-mounted dispensing systems.

About Innovative Medical Services

Innovative Medical Services (IMS) is a biosciences company that develops and markets technology-based products involving water purification/treatment, pest control and antimicrobial applications. The Company is currently America's leader in pharmaceutical water purification products and services using reverse osmosis technology. IMS has expanded beyond its niche pharmacy market by developing and marketing its Innovex line of EPA-approved pest control products using Triglycylboride(TM) technology and its Axenohl(R) antimicrobial disinfectant based upon its patented ionic silver technology.

Innovative Medical Services is headquartered in El Cajon, California (San Diego metropolitan area) and its common stock is listed on The Nasdaq Stock Market under the symbol "PURE".

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.